Logo

MNPR

Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc. • NASDAQ
$86.18 ▼ -1.35% (-1.18)
Market Cap $575.91 M
52w High $105.00
52w Low $20.16
Dividend Yield 0%
P/E -21.76
Volume 50.64K
Outstanding Shares 6.68M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $4.093M ▲ $-3.438M ▼ 0% $-0.48 ▼ $-3.438M ▼
Q2-2025 $0 $3.234M ▲ $-2.454M ▲ 0% $-0.35 ▲ $-2.454M ▲
Q1-2025 $0 $3.222M ▼ $-2.625M ▲ 0% $-0.38 ▲ $-3.222M ▲
Q4-2024 $0 $11.075M ▲ $-10.926M ▼ 0% $-0.95 ▼ $-10.926M ▼
Q3-2024 $0 $1.575M $-1.304M 0% $-0.11 $-1.304M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $143.675M ▲ $144.197M ▲ $2.64M ▲ $141.557M ▲
Q2-2025 $53.25M ▼ $53.866M ▼ $1.664M ▲ $52.202M ▼
Q1-2025 $54.553M ▼ $55.085M ▼ $1.492M ▼ $53.593M ▼
Q4-2024 $60.212M ▲ $60.291M ▲ $5.254M ▲ $55.037M ▲
Q3-2024 $6.02M $6.07M $1.123M $4.947M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.438M ▼ $-2.091M ▼ $-2.126M ▼ $92.392M ▲ $88.175M ▲ $-2.091M ▼
Q2-2025 $-2.454M ▲ $-1.077M ▲ $1.187M ▲ $-316.845K ▼ $-209.473K ▲ $-1.077M ▲
Q1-2025 $-2.625M ▲ $-5.663M ▼ $-325.828K ▲ $-115.682K ▼ $-6.105M ▼ $-5.663M ▼
Q4-2024 $-10.926M ▼ $-1.998M ▼ $-14.338M ▼ $56.137M ▲ $39.796M ▲ $-1.998M ▼
Q3-2024 $-1.304M $-1.073M $985.73K $-16.534K $-99.847K $-1.073M

Five-Year Company Overview

Income Statement

Income Statement Monopar is still a pure R&D biotech with no product revenue. Its income statement is simple: ongoing research and corporate costs lead to small but steady losses each year. The loss level has not exploded, but it is persistent, reflecting a company that is still firmly in the development stage. The sharp drop in earnings per share in the most recent year is driven much more by the share consolidation than by a big change in the underlying business performance.

Balance Sheet

Balance Sheet The balance sheet is very lean and almost entirely made up of cash, with no debt. That is clean and simple, but the absolute level of assets is quite small for a drug developer, which means the financial cushion is limited. Equity closely tracks the cash balance, signalling the company has been funded mainly through shareholders rather than borrowing. Over time, continued R&D will likely depend on periodic access to external capital.

Cash Flow

Cash Flow Cash flows show a consistent pattern of modest cash burn from operations and essentially no spending on physical assets or equipment. Free cash flow is therefore negative but relatively stable, driven by payroll, trials, and other R&D-related expenses. For a clinical-stage biotech, the burn rate appears measured rather than aggressive, but given the small cash base, the margin for error is not large if trials become more expensive or timelines extend.

Competitive Edge

Competitive Edge Competitively, Monopar is carving out a narrow but potentially attractive niche. It is an early mover in targeting the uPAR receptor with radiopharmaceuticals, using a theranostic approach that pairs imaging and treatment. This focus on specific cancer subsets and on a rare disease like Wilson Disease reduces head-to-head competition with large pharma. At the same time, Monopar is a very small player, with limited resources and high dependence on positive trial data, patent protection, and potential future partners to defend and extend its position.

Innovation and R&D

Innovation and R&D Innovation and R&D are the core of Monopar’s story. The MNPR‑101 platform, with versions for imaging and treatment using different radioisotopes, represents a focused attempt to build a new, targeted radiopharmaceutical franchise. The in-licensed Wilson Disease drug adds a late-stage, de-risked asset that could move the company toward commercialization if approved. Management has already shown discipline by discontinuing weaker programs to concentrate resources on these higher-conviction projects. The flip side is increased reliance on a small number of programs, so scientific or regulatory setbacks in these could have an outsized impact.

Summary

Monopar is a tiny, clinical-stage biotech with no revenue yet, a straightforward but persistently loss-making income statement, and a very simple, cash-heavy, debt-free balance sheet. Its cash burn is controlled but meaningful in light of its small capital base, keeping funding risk in focus. Strategically, the company is trying to build value through an early lead in uPAR‑targeted radiopharmaceuticals and a late-stage rare disease asset acquired from big pharma. Execution on clinical trials, regulatory filings, and potential partnerships will be critical, as success could be transformative, while setbacks would be keenly felt given the company’s size and concentration of bets.

NEWS

November 13, 2025 · 8:00 AM UTC

Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments

Read more

November 9, 2025 · 9:00 AM UTC

Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting® 2025

Read more

October 15, 2025 · 8:00 AM UTC

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

Read more

September 23, 2025 · 11:08 PM UTC

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Read more

September 23, 2025 · 11:07 PM UTC

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Read more